ライフサイエンスコーパス: transcatheter

1 A nonsurgical transcatheter alternative would be attractive.

2 enrolled in the RESOLVE study (Assessment of Transcatheter and Surgical Aortic Bioprosthetic Valve Dy

3 alve thrombosis have been reported with both transcatheter and surgical aortic valve bioprostheses.

4 ug Administration-approved studies comparing transcatheter and surgical aortic valve replacement with

5 ent characteristics, trends, and outcomes of transcatheter aortic and mitral valve catheter-based val

6 Off-label use of transcatheter aortic and pulmonary valve prostheses for

7 he mid- to long-term cognitive trajectory of transcatheter aortic valve (TAVR) recipients are scarce.

8 actice with a next-generation self-expanding transcatheter aortic valve are lacking.

9 Transcatheter aortic valve implantation (TAVI) has evolv

10 The proven efficacy of transcatheter aortic valve implantation (TAVI) in high-r

11 Of those, 1947 patients underwent transcatheter aortic valve implantation (TAVI) with the

12 ss the evolution of cognitive function after transcatheter aortic valve implantation (TAVI).

13 s in cardiac-coronary interaction because of transcatheter aortic valve implantation (TAVI).

14 remains a major predictor of mortality after transcatheter aortic valve implantation (TAVI).

15 (ASARVI) is still a major limiting factor in transcatheter aortic valve implantation and affects the

16 ventricular (RV) function and outcomes after transcatheter aortic valve implantation has not previous

17 ectiveness claims supporting the adoption of transcatheter aortic valve implantation in intermediate-

18 selected patients experiencing ASARVI after transcatheter aortic valve implantation is feasible, saf

19 Surgical aortic valve replacement or transcatheter aortic valve implantation is the sole effe

20 consecutively enrolled patients in the Swiss Transcatheter Aortic Valve Implantation registry.

21 liac occlusive disease undergoing subclavian transcatheter aortic valve implantation to avoid acute l

22 Transcatheter aortic valve implantation underwent progre

23 ectively included in the FRANCE TAVI (French Transcatheter Aortic Valve Implantation) registry.

24 Of 407 patients treated by transfemoral transcatheter aortic valve implantation, 110 experienced

25 190 patients underwent 1.5 Tesla CMR before transcatheter aortic valve implantation.

26 e risk stratification of patients undergoing transcatheter aortic valve implantation.

27 an independent predictor of mortality after transcatheter aortic valve implantation.

28 tructural information in patients undergoing transcatheter aortic valve implantation.

29 Given the expansion of transcatheter aortic valve procedures, including potenti

30 occurrence of paravalvular regurgitation and transcatheter aortic valve prosthesis failure seems to b

31 aortic (48%), both (2%), pulmonic (0.4%), or transcatheter aortic valve replacement (5%).

32 base who were recorded as having undergone a transcatheter aortic valve replacement (n = 3223), an en

33 s in a cohort of 8039 patients who underwent transcatheter aortic valve replacement (November 2011-Ju

34 A percutaneous approach with transcatheter aortic valve replacement (TAVR) and percut

35 nts with severe aortic stenosis undergoing a transcatheter aortic valve replacement (TAVR) and the ef

36 Data on sex-specific differences after transcatheter aortic valve replacement (TAVR) are confli

37 Data on 30-day readmissions after transcatheter aortic valve replacement (TAVR) are limite

38 sociated with PAD in a population undergoing transcatheter aortic valve replacement (TAVR) are unknow

39 With the approval of transcatheter aortic valve replacement (TAVR) for patien

40 Use of transcatheter aortic valve replacement (TAVR) for severe

41 Randomized trials support the use of transcatheter aortic valve replacement (TAVR) for the tr

42 Transcatheter aortic valve replacement (TAVR) has become

43 Transcatheter aortic valve replacement (TAVR) has become

44 Transcatheter aortic valve replacement (TAVR) has been i

45 In clinical trials, transcatheter aortic valve replacement (TAVR) has been s

46 Transcatheter aortic valve replacement (TAVR) has revolu

47 Data evaluating the outcomes of transcatheter aortic valve replacement (TAVR) in diabeti

48 ited data exist about safety and efficacy of transcatheter aortic valve replacement (TAVR) in patient

49 Data demonstrating the outcome of transcatheter aortic valve replacement (TAVR) in the ver

50 Transcatheter aortic valve replacement (TAVR) is a trans

51 Transcatheter aortic valve replacement (TAVR) is an alte

52 The risk for stroke after transcatheter aortic valve replacement (TAVR) is an impo

53 Residual aortic regurgitation (AR) following transcatheter aortic valve replacement (TAVR) is associa

54 t increased risk for surgery, self-expanding transcatheter aortic valve replacement (TAVR) is associa

55 Importance: Transcatheter aortic valve replacement (TAVR) is now a w

56 Direct transcatheter aortic valve replacement (TAVR) is regarde

57 Transcatheter aortic valve replacement (TAVR) is standar

58 The introduction of transcatheter aortic valve replacement (TAVR) led to ren

59 Valve-in-valve (VIV) transcatheter aortic valve replacement (TAVR) may be les

60 Neurological complications after transcatheter aortic valve replacement (TAVR) may be red

61 t intermediate surgical risk, treatment with transcatheter aortic valve replacement (TAVR) or surgica

62 he potential for functional recovery after a transcatheter aortic valve replacement (TAVR) or surgica

63 ferential impact of sex has been observed in transcatheter aortic valve replacement (TAVR) outcomes f

64 phic outcomes of patients who underwent redo transcatheter aortic valve replacement (TAVR) procedures

65 permanent pacemaker implantation (PPI) after transcatheter aortic valve replacement (TAVR) remains co

66 Patient selection for transcatheter aortic valve replacement (TAVR) should inc

67 atients at high risk for poor outcomes after transcatheter aortic valve replacement (TAVR) to help gu

68 The use of transcatheter aortic valve replacement (TAVR) to treat a

69 Transcatheter aortic valve replacement (TAVR) was approv

70 clinical and device performance outcomes of transcatheter aortic valve replacement (TAVR) with a nex

71 ents with severe aortic valve stenosis after transcatheter aortic valve replacement (TAVR) with a sel

72 ssociated with increased mortality following transcatheter aortic valve replacement (TAVR) with first

73 Conscious sedation is used during transcatheter aortic valve replacement (TAVR) with limit

74 Transcatheter aortic valve replacement (TAVR) with the S

75 Early experience with transcatheter aortic valve replacement (TAVR) within fai

76 nscaval access may enable fully percutaneous transcatheter aortic valve replacement (TAVR) without th

77 Transcatheter aortic valve replacement (TAVR), because o

78 In patients with aortic stenosis undergoing transcatheter aortic valve replacement (TAVR), studies h

79 eening and management in patients undergoing transcatheter aortic valve replacement (TAVR).

80 pact of variations in exercise capacity post-transcatheter aortic valve replacement (TAVR).

81 ociated with adverse clinical outcomes after transcatheter aortic valve replacement (TAVR).

82 s may predict outcome in patients undergoing transcatheter aortic valve replacement (TAVR).

83 had infective endocarditis after undergoing transcatheter aortic valve replacement (TAVR).

84 heter heart valve (THV) thrombosis following transcatheter aortic valve replacement (TAVR).

85 mbolization is a frequent complication after transcatheter aortic valve replacement (TAVR).

86 valve hemodynamic deterioration (VHD) after transcatheter aortic valve replacement (TAVR).

87 y, frailty, and disability on outcomes after transcatheter aortic valve replacement (TAVR).

88 (Cerebral Protection in Transcatheter Aortic Valve Replacement [SENTINEL]; NCT02

89 ion abnormalities are a common finding after transcatheter aortic valve replacement and often result

90 and procedural evolution, support the use of transcatheter aortic valve replacement as the preferred

91 We identified 42 189 patients who underwent transcatheter aortic valve replacement between the years

92 The Vancouver transcatheter aortic valve replacement clinical pathway

93 The implementation of a transcatheter aortic valve replacement clinical pathway

94 The 54,782 patients with transcatheter aortic valve replacement demonstrated decr

95 valence and treatment distribution including transcatheter aortic valve replacement eligibility in lo

96 ients with CoreValve, Evolut R, and SAPIEN 3 transcatheter aortic valve replacement enrolled in the R

97 Placement of Aortic Transcatheter Valves) of transcatheter aortic valve replacement for high-risk (HR

98 Transcatheter aortic valve replacement for incidence of

99 Transcatheter aortic valve replacement has become the pr

100 The rapid growth of transcatheter aortic valve replacement has been fuelled

101 In recent years, use of transcatheter aortic valve replacement has expanded to i

102 cance of early LVEF recovery after CoreValve transcatheter aortic valve replacement have not been des

103 nosis, with over 25% patients presenting for transcatheter aortic valve replacement having chronic ki

104 d to the unique requirements of transfemoral transcatheter aortic valve replacement in contemporary p

105 (MR) angiography for vascular mapping before transcatheter aortic valve replacement in patients with

106 (Transcaval Access for Transcatheter Aortic Valve Replacement in People With No

107 lied to 3491 consecutive patients undergoing transcatheter aortic valve replacement in Switzerland be

108 The benefit of transcatheter aortic valve replacement in terms of quali

109 th baseline and discharge ECGs who underwent transcatheter aortic valve replacement in the Placement

110 The persistence of severe PH after transcatheter aortic valve replacement is a stronger pre

111 The experience with transcatheter aortic valve replacement is increasing wor

112 Transcatheter aortic valve replacement might be a good a

113 However, the transcatheter aortic valve replacement patient presents

114 e maturity of THV technology, variability in transcatheter aortic valve replacement practice, end poi

115 ed Risk of Mortality [PROM]) of 7% to 6% and transcatheter aortic valve replacement PROM (TVT PROM) o

116 al neurological events rates associated with transcatheter aortic valve replacement raised concerns t

117 ARC (Valve Academic Research Consortium) for transcatheter aortic valve replacement set the standard

118 0-day outcomes with the low-profile SAPIEN 3 transcatheter aortic valve replacement system demonstrat

119 Although transcatheter aortic valve replacement thrombosis is a m

120 of intraoperative implanted to a theoretical transcatheter aortic valve replacement valve size result

121 mplanted valve size and (2) to a theoretical transcatheter aortic valve replacement valve size.

122 an aortic annulus area <400 mm(2) undergoing transcatheter aortic valve replacement with either a sel

123 afety profile with low clinical event rates, transcatheter aortic valve replacement with the ACURATE

124 Transcatheter aortic valve replacement with the SAPIEN 3

125 echanical interventions for aortic stenosis (transcatheter aortic valve replacement) may alter the ri

126 tients with normally functioning surgical or transcatheter aortic valve replacement, 24 patients with

127 In patients with renal impairment undergoing transcatheter aortic valve replacement, FE MR angiograph

128 After transcatheter aortic valve replacement, the presence of

129 multicenter, non-US cohort of patients with transcatheter aortic valve replacement, the validation o

130 To exclude patients who may have undergone transcatheter aortic valve replacement, we conducted a s

131 .5 and 350.6 to identify patients undergoing transcatheter aortic valve replacement.

132 cement and 1.0 million patients eligible for transcatheter aortic valve replacement.

133 ventricular ejection fraction recovery post-transcatheter aortic valve replacement.

134 linical and echocardiographic outcomes after transcatheter aortic valve replacement.

135 in-hospital mortality in patients undergoing transcatheter aortic valve replacement.

136 ents with severe aortic stenosis considering transcatheter aortic valve replacement.

137 nt of early outcome in patients eligible for transcatheter aortic valve replacement.

138 dered to negatively affect the outcome after transcatheter aortic valve replacement.

139 home at the earliest time after transfemoral transcatheter aortic valve replacement.

140 ently associated with 30-day mortality after transcatheter aortic valve replacement.

141 F will have a marked early improvement after transcatheter aortic valve replacement.

142 on clinical outcomes in patients undergoing transcatheter aortic valve replacement.

143 ve clinical outcomes, in patients undergoing transcatheter aortic valve replacement.

144 ventricular ejection fraction (LVEF) before transcatheter aortic valve replacement.

145 Transcatheter aortic valve replacement.

146 130-610 210) low-risk patients eligible for transcatheter aortic valve replacement.

147 % and 40.6% larger if patients had undergone transcatheter aortic valve replacement.

148 bclinical leaflet thrombosis in surgical and transcatheter aortic valves and the effect of novel oral

149 ic stenosis, survival rates are similar with transcatheter aortic-valve replacement (TAVR) and surgic

150 Although transcatheter aortic-valve replacement (TAVR) is an acce

151 The authors undertook this transcatheter approach for an adult with untreated conge

152 ho require aortic valve replacement, but the transcatheter approach is established for high-risk pati

153 V), which can be implanted via a surgical or transcatheter approach.

154 Thus transcatheter approaches to FTR are raising great intere

155 Purpose To assess response to transcatheter arterial chemoembolization (TACE) based on

156 Therapies included transcatheter arterial chemoembolization, transarterial

157 selective angiography, which was followed by transcatheter arterial embolization (TAE) of the BAA and

158 circulating angiogenesis factors after bland transcatheter arterial embolization (TAE), a purely isch

159 g mechanical PAS, severe other valve disease transcatheter AVR, and LV ejection fraction <50%).

160 reporting, akin to other multidisciplinary, transcatheter-based therapies.

161 Patients undergoing transcatheter BHV replacement are at risk for thromboemb

162 emains an important drawback of surgical and transcatheter bioprostheses.

163 valve replacement (TAVR) may be reduced with transcatheter cerebral embolic protection (TCEP).

164 tested the feasibility and safety of a novel transcatheter device and assessed its early performance

165 ticenter, early feasibility study of a novel transcatheter device to plicate the tricuspid annulus (T

166 COUT trial confirmed the safety of the novel transcatheter device, which reduced TA and EROA, increas

167 Numerous transcatheter devices are currently in early clinical tr

168 ssment of valve morphology and function, and transcatheter devices typically require intraprocedural

169 discuss imaging requirements for the current transcatheter devices under development for the treatmen

170 oints reflecting safety and effectiveness of transcatheter devices, and defining single and composite

171 m was developed for selective intra-arterial transcatheter drug delivery to liver tumors.

172 This experimental work demonstrated that the transcatheter edge-to-edge repair technique is a feasibl

173 ution of imaging abnormalities, and elevated transcatheter gradients with anticoagulation or surgical

174 ACURATE neo, n=129) or a balloon-expandable transcatheter heart valve (Edwards SAPIEN 3, n=117).

175 lve replacement with either a self-expanding transcatheter heart valve (Symetis ACURATE neo, n=129) o

176 traditionally requires stricter criteria for transcatheter heart valve (THV) approval, including rand

177 The CENTERA transcatheter heart valve (THV) is a low-profile, self-e

178 hy is useful for determining the appropriate transcatheter heart valve (THV) size in patients with se

179 TAVR) with a next-generation, self-expanding transcatheter heart valve (THV) system in patients with

180 c echocardiographic follow-up, the advent of transcatheter heart valve (THV) technologies coupled wit

181 al implications, and predisposing factors of transcatheter heart valve (THV) thrombosis following tra

182 Transcatheter heart valve (THV) thrombosis has been incr

183 udy of the Edwards CENTERA-EU Self-Expanding Transcatheter Heart Valve [CENTERA-2]; NCT02458560).

184 eir consecutive experience with the SAPIEN 3 transcatheter heart valve, dependent on patient consent,

185 ational registry of the latest generation of transcatheter heart valve, the SAPIEN 3 (Edwards Lifesci

186 R with a third-generation balloon-expandable transcatheter heart valve.

187 valve-in-valve implantation using different transcatheter heart valves (THV).

188 valves revealed excellent durability of the transcatheter heart valves and SAVR.

189 tive; however, comparative data on different transcatheter heart valves are missing.

190 on was caused by structural deterioration of transcatheter heart valves in only 5 patients.

191 This large, core laboratory-based study of transcatheter heart valves revealed excellent durability

192 emodynamic performance of balloon-expandable transcatheter heart valves.

193 Cirrhosis was induced in swine by means of transcatheter infusion of ethanol and iodized oil into t

194 Intrahepatic transcatheter infusion procedures were performed in rats

195 In nonrandomized, open-label studies, a transcatheter interatrial shunt device (IASD, Corvia Med

196 A novel transcatheter interatrial shunt device has been develope

197 cle, we give the rationale for a therapeutic transcatheter interatrial shunt device in HFpEF, and we

198 ding was common among patients who underwent transcatheter intervention using large-bore catheters an

199 patients had experienced either surgical or transcatheter intervention.

200 antages in the evaluation of new devices and transcatheter interventions in chronic heart failure and

201 Bleeding complications after percutaneous transcatheter interventions that used large-bore cathete

202 Transcatheter interventions to treat mitral and tricuspi

203 reprocedural evaluation and implications for transcatheter interventions.

204 (Frailty Assessment Before Cardiac Surgery & Transcatheter Interventions; NCT01845207).

205 e, we provide an updated overview of current transcatheter left atrial appendage closure devices and

206 In addition, as more patients undergo transcatheter left valve interventions, developing trans

207 ion (SAM) and mitral regurgitation using the transcatheter mitral clip system.

208 The 2,556 patients who underwent transcatheter mitral leaflet clip in 2015 were similar t

209 a useful tool for procedural guidance during transcatheter mitral repair.

210 Transcatheter mitral technologies have potential as solu

211 evaluations will help to define the role of transcatheter mitral therapy as a potentially exciting n

212 Recently, multiple technologies for transcatheter mitral therapy have emerged, with the pote

213 ore biomechanically appropriate to determine transcatheter mitral valve implantation size and eligibi

214 T assessment of the D-shaped MA to determine transcatheter mitral valve implantation size.

215 re mitral regurgitation being considered for transcatheter mitral valve implantation who had undergon

216 Using the devices currently available, transcatheter mitral valve repair (TMVr) remains challen

217 hors examined the commercial experience with transcatheter mitral valve repair for the treatment of m

218 Our findings demonstrate that commercial transcatheter mitral valve repair is being performed in

219 te use programme in which patients underwent transcatheter mitral valve repair using the Edwards PASC

220 gistry on patients commercially treated with transcatheter mitral valve repair were analyzed.

221 Transcatheter mitral valve repair with a MitraClip devic

222 Transcatheter mitral valve repair, particularly edge-to-

223 Limited data exist regarding transcatheter mitral valve replacement (TMVR) for patien

224 More recently, transcatheter mitral valve replacement (TMVR) has emerge

225 Transcatheter mitral valve replacement (TMVR) is a poten

226 Transcatheter mitral valve replacement (TMVR) may be an

227 afety and Performance of the Twelve Intrepid Transcatheter Mitral Valve Replacement System in High Ri

228 equired to determine the long-term impact of transcatheter MV repair in this patient population.

229 Transcatheter MV repair was performed for degenerative d

230 the initial U.S. commercial experience with transcatheter MV repair.

231 We hypothesized that transcatheter needle injection of caustic agents doped w

232 In this historical comparison study, the transcatheter pacemaker met the prespecified safety and

233 ective multicenter study without controls, a transcatheter pacemaker was implanted in patients who ha

234 A leadless intracardiac transcatheter pacing system has been designed to avoid t

235 ptal aneurysm or large interatrial shunt, to transcatheter PFO closure plus long-term antiplatelet th

236 of these disease states, minimally invasive transcatheter portal venous interventions have been deve

237 Other transcatheter procedures are in rapid development.

238 TVIV with commercially available transcatheter prostheses is technically and clinically s

239 implantation of the novel Medtronic Harmony transcatheter pulmonary valve (hTPV) and to assess its e

240 peak conduit pressure gradient acutely after transcatheter pulmonary valve implantation (39 versus 10

241 ts underwent placement of >/=1 stents before transcatheter pulmonary valve implantation.

242 Transcatheter pulmonary valve replacement (TPVR) has bec

243 Transcatheter pulmonary valve replacement (TPVR) is an e

244 Follow-up of transcatheter pulmonary valve replacement (TPVR) with th

245 The incidence of Melody transcatheter pulmonary valve stent fracture (3.4%) and

246 TMVR may offer some advantages over transcatheter repair by providing a more complete and re

247 ational study, the safety and feasibility of transcatheter repair of chronic severe TR with the Mitra

248 atheter left valve interventions, developing transcatheter solutions for functional TR has gained gre

249 Use of transcatheter techniques, both repair and replacement, i

250 ioprosthetic aortic valves, more commonly in transcatheter than in surgical valves.

251 Novel transcatheter therapies have begun to emerge for the tre

252 Patients underwent transcatheter, transapical delivery of a self-expanding

253 Transcatheter treatment of TR with the MitraClip system

254 Recently, novel transcatheter treatment options were developed for treat

255 valve replacement in the Placement of AoRTic TraNscathetER Valve (PARTNER) trial.

256 XT valve or SAVR in the Placement of Aortic Transcatheter Valve 2 Trial and were followed up for 2 y

257 s with Food and Drug Administration-approved transcatheter valve devices performed in the United Stat

258 Transcatheter valve implantation inside failed bioprosth

259 Supra-annular transcatheter valve position may be advantageous in achi

260 ombosis of bioprosthetic aortic valves after transcatheter valve replacement (TAVR) and surgical aort

261 dures and echocardiographic imaging used for transcatheter valve replacement or valve repair.

262 ar aortic regurgitation after self-expanding transcatheter valve replacement without an increase in c

263 implications of these findings in the era of transcatheter valve replacement.

264 2 patients who underwent TAVR as part of the Transcatheter Valve Therapies Registry, we examined rate

265 acic Surgeons/American College of Cardiology Transcatheter Valve Therapy (STS/ACC TVT) Registry.

266 urgeons (STS)/American College of Cardiology Transcatheter Valve Therapy (TVT) Registry captures all

267 acic Surgeons/American College of Cardiology Transcatheter Valve Therapy (TVT) Registry from November

268 The Transcatheter Valve Therapy (TVT) registry model was rec

269 acic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry (November 2011 to O

270 (STS/ACC Transcatheter Valve Therapy Registry [TVT Registry]; NCT

271 Transcatheter Valve Therapy Registry analyses using this

272 Using data from the Transcatheter Valve Therapy Registry and Society of Thor

273 conducted at 395 hospitals submitting to the Transcatheter Valve Therapy Registry from 2011 through 2

274 S AND Using the Society of Thoracic Surgeons/Transcatheter Valve Therapy Registry linked to Medicare

275 racic Surgery/American College of Cardiology Transcatheter Valve Therapy Registry on patients commerc

276 acic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry was used to charact

277 acic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry were used for in-ho

278 acic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry.

279 s and the STS/American College of Cardiology Transcatheter Valve Therapy Registry.

280 AVR in the United States are included in the Transcatheter Valve Therapy Registry.

281 acic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry.

282 Surgeons/American College of Cardiology TVT (Transcatheter Valve Therapy) Registry.

283 VR, with prior right bundle-branch block and transcatheter valve type and implantation depth being th

284 ater body mass index, and the use of a 23-mm transcatheter valve were associated with higher rates of

285 in the PARTNER I trial (Placement of Aortic Transcatheter Valve) who had systolic blood pressure (SB

286 an important adjunct to surgical AVR in the transcatheter valve-in-valve era.

287 Transcatheter valve-in-valve implantation is an establis

288 s versus 101 (13%) of 752 with thrombosis of transcatheter valves (p=0.001).

289 patients enrolled in the Placement of Aortic Transcatheter Valves (PARTNER) 1 Trial with successful T

290 d analysis of PVR in the Placement of Aortic Transcatheter Valves (PARTNER) II SAPIEN 3 trial, conduc

291 nalysis of data from the Placement of Aortic Transcatheter Valves (PARTNER) randomized clinical trial

292 (The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves [PARTNER II]; NCT01314313).

293 either balloon-expandable or self-expanding transcatheter valves and results in reduced residual tra

294 There is anecdotal experience with use of transcatheter valves by either a catheter-based approach

295 on-expandable (n=8) or self-expanding (n=12) transcatheter valves in Mitroflow, Carpentier-Edwards Pe

296 discrimination as in the Placement of Aortic Transcatheter Valves Trial cohorts (c-indexes, 0.637 to

297 the multicenter PARTNER (Placement of Aortic Transcatheter Valves) 2 VIV trial and continued access r

298 e initial PARTNER trial (Placement of Aortic Transcatheter Valves) of transcatheter aortic valve repl

299 (TAVR) with first and second generations of transcatheter valves.

300 VR in the PARTNER trial (Placement of Aortic Transcatheter Valves; as-treated), including the continu